Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

    Argenica completes production of brain stroke drug, prepares for Phase 2 trial

    Biotech company Argenica Therapeutics Limited (ASX: AGN), which is developing novel therapeutics to reduce brain tissue death after stroke, has completed the production of its neuroprotective peptide candidate ARG-007 in powder form. The Company is gearing up for its Phase 2 clinical trials, and the final manufacturing of the sterile drug product in vials is

    Read More
    Public
  • Are New York’s finest now New York’s most autonomous? Ask Nightingale Intelligent Systems
    • News

    Are New York’s finest now New York’s most autonomous? Ask Nightingale Intelligent Systems

    The largest police department in the United States is set to unveil a squadron of drones that will act as first responders to scenes across the city, powered by artificial intelligence and supplied by drone company Nightingale Intelligent Systems (ASX: NGL). The 3-year supply contract is with the unnamed Police Department but a simple Google

    Read More
    Public
  • Smart ways to survive: PlaySide inks deal with Warner Bros subsidiary for multi-game license
    • News

    Smart ways to survive: PlaySide inks deal with Warner Bros subsidiary for multi-game license

    Video game developer PlaySide Studios (ASX: PLY), the studio behind popular games like “Dumb Ways to Die” and “Age of Darkness: Final Stand”, has signed a multi-game license deal with Warner Bros. Interactive Entertainment, a subsidiary of Warner Bros. Discovery, Inc. The agreement grants PlaySide access to a well-known intellectual property, allowing the development of

    Read More
    Public
  • Fed sees three rate cuts in 2024
    • Market Update

    Fed sees three rate cuts in 2024

    The XJO is expected to open higher this morning following a strong rally in the U.S overnight. Their futures are flat this morning. The U.S has obviously interpreted the news surrounding next year’s guidance on monetary policy extraordinary well and their positivity should directly flow into our market. We should open near 7,350 resistance, but

    Read More
    Public
  • Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib
    • News

    Syntara doses first blood cancer patient for combination treatment of SNT-5505 and ruxolitinib

    Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where

    Read More
    Public
  • Baker Hughes commits to substantial investment in SRJ’s BoltEx flange clamps following product training session
    • News

    Baker Hughes commits to substantial investment in SRJ’s BoltEx flange clamps following product training session

    Following a product training session conducted by asset integrity management solution SRJ Technologies (ASX: SRJ) with Baker Hughes’ global engineering team, the latter has announced a commitment to procure SRJ’s BoltEx® flange clamps. SRJ, a specialised provider of engineering services and containment management solutions, disclosed that Baker Hughes’ initial order amounted to an impressive $231,000.

    Read More
    Public
  • «
  • ‹
  • 139
  • 140
  • 141
  • 142
  • 143
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.